Scaling-up recombinant plasmid DNA for clinical trial: Current concern, solution and status

被引：25
作者：
Ismail, Ruzila [2 ]
Allaudin, Zeenathul Nazariah [1 ]
Lila, Mohd-Azmi Mohd [1 ]
机构：
[1] Univ Putra Malaysia, Fac Vet Med, Dept Pathol & Microbiol, Serdang 43400, Selangor, Malaysia
[2] Univ Putra Malaysia, Inst Biosci, Lab Immunotherapeut & Vaccines, Serdang 43400, Selangor, Malaysia
来源：
VACCINE | 2012年 / 30卷 / 41期
关键词：
DNA vaccine; Host genome; Plasmid DNA; Resistance marker; Synthetic vector; TRANSGENE EXPRESSION; GENE-THERAPY; REPLICATION ORIGIN; SYNTHETIC PROMOTER; CPG MOTIFS; SELECTION; SEQUENCE; VECTORS; MAINTENANCE; VACCINE;
D O I：
10.1016/j.vaccine.2012.02.061
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Gene therapy and vaccines are rapidly developing field in which recombinant nucleic acids are introduced in mammalian cells for enhancement, restoration, initiation or silencing biochemical function. Beside simplicity in manipulation and rapid manufacture process, plasmid DNA-based vaccines have inherent features that make them promising vaccine candidates in a variety of diseases. This present review focuses on the safety concern of the genetic elements of plasmid such as propagation and expression units as well as their host genome for the production of recombinant plasmid DNA. The highlighted issues will be beneficial in characterizing and manufacturing plasmid DNA for save clinical use. Manipulation of regulatory units of plasmid will have impact towards addressing the safety concerns raised in human vaccine applications. The gene revolution with plasmid DNA by alteration of their plasmid and production host genetics will be promising for safe delivery and obtaining efficient outcomes. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5914 / 5920
页数：7
相关论文
共 83 条
[41]   Synthetic intron improves transduction efficiency of trans-splicing adeno-associated viral vectors [J].
Lai, Yi ;
Yue, Yongping ;
Liu, Mingju ;
Duan, Dongsheng .
HUMAN GENE THERAPY, 2006, 17 (10) :1036-1042
[42]   Muscle-specific enhancement of gene expression by incorporation of SV/40 enhancer in the expression plasmid [J].
Li, S ;
MacLaughlin, FC ;
Fewell, JG ;
Gondo, M ;
Wang, J ;
Nicol, F ;
Dean, DA ;
Smith, LC .
GENE THERAPY, 2001, 8 (06) :494-497
[43]   Increased level and duration of expression in muscle by co-expression of a transactivator using plasmid systems [J].
Li, S ;
MacLaughlin, FC ;
Fewell, JG ;
Li, Y ;
Mehta, V ;
French, MF ;
Nordstrom, JL ;
Coleman, M ;
Belagali, NS ;
Schwartz, RJ ;
Smith, LC .
GENE THERAPY, 1999, 6 (12) :2005-2011
[44]   Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences [J].
Li, XY ;
Eastman, EM ;
Schwartz, RJ ;
Draghia-Akli, R .
NATURE BIOTECHNOLOGY, 1999, 17 (03) :241-245
[45]   PhiC31 integrase induces a DNA damage response and chromosomal rearrangements in human adult fibroblasts [J].
Liu, Jian ;
Skjorringe, Tina ;
Gjetting, Torben ;
Jensen, Thomas G. .
BMC BIOTECHNOLOGY, 2009, 9
[46]  
Lou MTN, 2010, Toxin-antitoxin System and Applications Thereof, Patent No. [US20100028378, 20100028378]
[47]   Advances in high-capacity extrachromosomal vector technology: Episomal maintenance, vector delivery, and transgene expression [J].
Lufino, Michele M. P. ;
Edser, Pauline A. H. ;
Wade-Martins, Richard .
MOLECULAR THERAPY, 2008, 16 (09) :1525-1538
[48]   Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system [J].
Luke, Jeremy ;
Carnes, Aaron E. ;
Hodgson, Clague P. ;
Williams, James A. .
VACCINE, 2009, 27 (46) :6454-6459
[49]  
Mairhofer Jurgen, 2008, Biotechnology Journal, V3, P83, DOI 10.1002/biot.200700141
[50]   Immunology of DNA vaccines: CpG motifs and antigen presentation [J].
Manders, P ;
Thomas, R .
INFLAMMATION RESEARCH, 2000, 49 (05) :199-205
123456789